Spinal Muscular Atrophy Market to Grow at a Substantial Growth Rate During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Scholar Rock, Alcyone Therapeutics, Cytokinetics, Roche

February 28 02:58 2023
Spinal Muscular Atrophy Market to Grow at a Substantial Growth Rate During the Forecast Period (2022-2032) -  DelveInsight | Key Companies - Scholar Rock, Alcyone Therapeutics, Cytokinetics, Roche
Delveinsight Business Research LLP
The Spinal Muscular Atrophy Market is anticipated to evolve immensely in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period.

DelveInsight’s “Spinal Muscular Atrophy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Spinal Muscular Atrophy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Spinal Muscular Atrophy market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Spinal Muscular Atrophy Market

Spinal Muscular Atrophy: An Overview

Spinal muscular atrophy (SMA) is an autosomal recessive rare neuromuscular disorder that is characterized by progressive muscle wasting because of the loss of motor neurons in the spinal cord (anterior horn), which controls voluntary muscle movement. SMA is one of the most common causes of infant death and mobility impairment. It mostly affects proximal muscles and respiratory muscles. The most common form of SMA is known as ‘5q SMA’ due to its genetic cause.

Treatment of Spinal Muscular Atrophy is quite challenging however, in an overall perspective, recent and extensive research and development activities being conducted for the development of novel drugs, increase understanding of the related comorbidities, along with the upcoming pipeline drugs, are expected to create a lucrative environment for the growth of SMA treatment market. Several major pharma and biotech giants, such as Cytokinetics, Scholar Rock, Roche, and others, are involved in developing treatments for SMA.

The emerging pipeline of Spinal Muscular Atrophy has a few promising lead candidates in various stages of development, which are yet to be launched. The potential candidates with promising results include Reldesemtiv (Cytokinetics), Apitegromab (Scholar Rock), GYM329 (Roche), and others.

Spinal Muscular Atrophy Market Key Facts

  • According to the National Organization for Rare Disorders (NORD), the prevalence of all types of SMA has been estimated to be 4-7.8 per 100,000 live births. Approximately 80% of SMA patients have the Werdnig-Hoffmann form, i.e., Type 1 SMA. It further stated that the condition is diagnosed in only 150 to 200 people. Moreover, 1 in 50 people (approximately 6 million Americans) is a carrier.

  • According to the study conducted by Lally et al. (2017), SMA genotype prevalence at birth consistently ranges from 8.5–10.3 per 100,000 live births, with a mid-range estimate of 9.4 per 100,000. Among infants born with an SMA genotype, it was reported that ~58% would develop SMA Type I, 29% would develop Type II, and 13% will develop Type III, respectively. 

  • National Institute for Health and Care Excellence (NICE) (2018) reported that SMA affects an estimated 1 in 6,000 to 1 in 10,000 births worldwide. It is estimated that about 100 people are born with SMA per year in the UK, and there are currently between 1,200 and 2,500 children and adults in the UK living with SMA. 

Spinal Muscular Atrophy Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Spinal Muscular Atrophy market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Spinal Muscular Atrophy market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Spinal Muscular Atrophy Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Spinal Muscular Atrophy Epidemiology Segmented by –

  • Total Prevalent Population of Spinal Muscular Atrophy (SMA) in the 7MM (2019–2032)

  • Age-specific Prevalence of Spinal Muscular Atrophy (SMA) in the 7MM (2019–2032)

  • Type-specific Prevalence of Spinal Muscular Atrophy (SMA) in the 7MM (2019–2032)

Spinal Muscular Atrophy Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Spinal Muscular Atrophy market or expected to be launched during the study period. The analysis covers the Spinal Muscular Atrophy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Spinal Muscular Atrophy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Spinal Muscular Atrophy Market Will Evolve and Grow by 2032 @ 


Spinal Muscular Atrophy Therapeutics Analysis

Several major pharma and biotech giants are in developing therapies for Spinal muscular atrophy. Currently, Scholar Rock is leading the therapeutics market with its Spinal muscular atrophy drug candidates in the most advanced stage of clinical development. 

The Leading Companies in the Spinal Muscular Atrophy Therapeutics Market Include:

  • Alcyone Therapeutics

  • Amniotics

  • Amylon Therapeutics

  • AndroScience Corporation

  • Astellas Pharma

  • Aurimed Pharma

  • Biogen

  • Biohaven Pharmaceuticals

  • CANbridge Pharmaceuticals Inc.

  • Catalyst Pharmaceuticals

  • Exicure

  • Hanugen Therapeutics

  • Hoffmann-La Roche

  • NMD Pharma

  • Scholar Rock

  • Voyager Therapeutics

And Many Others

Spinal Muscular Atrophy Therapies Covered in the Report Include:

  • Apitegromab: Scholar Rock

  • ACTX-401: Alcyone Therapeutics

  • Reldesemtiv: Cytokinetics

  • GYM329: Roche

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @


Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Spinal Muscular Atrophy Competitive Intelligence Analysis

4. Spinal Muscular Atrophy Market Overview at a Glance

5. Spinal Muscular Atrophy Disease Background and Overview

6. Spinal Muscular Atrophy Patient Journey

7. Spinal Muscular Atrophy Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Spinal Muscular Atrophy Treatment Algorithm, Current Treatment, and Medical Practices

9. Spinal Muscular Atrophy Unmet Needs

10. Key Endpoints of Spinal Muscular Atrophy Treatment

11. Spinal Muscular Atrophy Marketed Products

12. Spinal Muscular Atrophy Emerging Drugs and Latest Therapeutic Advances

13. Spinal Muscular Atrophy Seven Major Market Analysis

14. Attribute Analysis

15. Spinal Muscular Atrophy Market Outlook (In US, EU5, and Japan)

16. Spinal Muscular Atrophy Access and Reimbursement Overview

17. KOL Views on the Spinal Muscular Atrophy Market

18. Spinal Muscular Atrophy Market Drivers

19. Spinal Muscular Atrophy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @



Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving pharmaceutical market today @ Pharmaceutical Partner Identification Solutions

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/